Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 231 Florida 173 Arizona 113 Illinois 109 Georgia 105
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company59 AstraZeneca58 AbbVie48 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC39 Clear sponsor filter
State
California231 Florida173 Arizona113 Illinois109 Georgia105
All 48 states
Target enrolment
to

Trials with a site in Connecticut

58 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
AstraZeneca
Phase 3
15,100
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2025-06-04
Active, closed
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois
2025-05-06
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Recruiting
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Recruiting
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Recruiting
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Recruiting
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Active, closed
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Recruiting
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Active, closed
AstraZeneca
Phase 3
2,554
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-03-29
Recruiting
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Recruiting
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
Recruiting
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Active, closed
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
AstraZeneca
Phase 3
644
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Michigan
2022-05-16
Recruiting
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Active, closed
AstraZeneca
Phase 3
927
Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada
2021-10-25
Active, closed
AstraZeneca
Phase 3
712
California, Connecticut, District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa
2021-08-05
Active, closed
AstraZeneca
Phase 3
893
Arizona, California, Colorado, Connecticut, Delaware, Kentucky, Maryland, Massachusetts
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,012
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Michigan
2020-07-13
Active, closed
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
AstraZeneca
Phase 3
1,063
Alabama, California, Connecticut, Illinois, Iowa, Kansas, Kentucky, Louisiana
2018-11-16
Active, closed
AstraZeneca
Phase 3
1,246
Alabama, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Kansas
2018-09-27
Active, closed
AstraZeneca
Phase 3
730
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2018-09-27
Active, closed
AstraZeneca
Phase 2
273
Alabama, Alaska, Arizona, Colorado, Connecticut, Illinois, Indiana, Kentucky
2018-03-07
Active, closed
AstraZeneca
Phase 3
987
Alabama, Arizona, Arkansas, California, Connecticut, Georgia, Indiana, Kansas
2017-03-27
Active, closed
AstraZeneca
Phase 1
117
California, Connecticut, Florida, New York, Ohio, Tennessee
2016-12-28
Active, closed
AstraZeneca
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Maryland, Minnesota
2015-07-21
Active, closed
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2013-08-26
Active, closed
AstraZeneca
Phase 3
736
Arizona, California, Connecticut, Florida, Illinois, Maryland, Michigan, Missouri
2005-02-13
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Connecticut that also match the filters currently applied.

How many clinical trials are recruiting in Connecticut?

29 of the 58 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 29 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Connecticut), 58 studies
PhaseStudiesRecruitingShare
Phase 3492484.5%
Phase 2538.6%
Phase 1203.4%
Observational111.7%
Phase 1/2111.7%

Most active sponsors

Lead sponsors with the most studies (Connecticut)
Lead sponsorStudiesRecruiting
AstraZeneca5829
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.